Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

Leukemia volume 29, pages 2263–2266 (2015)Cite this article

Subjects

Chronic myelogenous leukemia (CML) is defined at the molecular level by the presence of t(9;22)(q34;q11.2)/BCR-ABL. Clonal evolution with additional chromosomal changes (ACAs) in CML is common and often associated with disease progression1 and resistance to tyrosine kinase inhibitor (TKI) therapy.2, 3, 4 ACAs are present in ~30% of patients in accelerated phase (AP) and 50–80% of patients in blast phase (BP) of CML.5, 6 The most common ACAs include trisomy 8, an extra Philadelphia chromosome (Ph), i(17)(q10), and trisomy 19.7, 8 These are ‘major route’ changes as described in the literature.9, 10 Other less common ACAs represent ‘minor route’ changes. The emergence of ACAs, especially major route changes, is regarded as a criterion for AP in CML in the WHO classification11 and the European LeukemiaNET.10

Although ACAs are considered as a sign of disease progression in CML, the significance of each individual chromosomal change remains largely unknown. Trisomy 8 is a common ACA in CML and belongs to one of the major route chromosomal changes. Its impact on TKI treatment response and overall prognosis, however, is not fully understood. Although a few studies have indicated that trisomy 8 in CML may be associated with a poorer prognosis,2, 3, 12 those studies were limited by the small number of patients with trisomy 8 (nine, three and nine cases, respectively) and the confounding presence of other concurrent ACAs (13/21, 62%). Such limitations have compromised assessment of the definitive impact of trisomy 8 in CML. In this study we explored the impact of trisomy 8, isolated or present concurrently with other ACAs, on the response to TKIs treatment and clinical outcome in a cohort of 2015 CML patients admitted in our hospital during the TKI era. Conventional cytogenetic data were available for all patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Ernst T, Hochhaus A . Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012; 39: 58–66.

    Article  CAS  PubMed  Google Scholar 

  2. Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760–6768.

    Article  CAS  PubMed  Google Scholar 

  3. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012; 120: 761–767.

    Article  CAS  PubMed  Google Scholar 

  4. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794–3800.

    Article  CAS  PubMed  Google Scholar 

  5. Johansson B, Fioretos T, Mitelman F . Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76–94.

    Article  CAS  PubMed  Google Scholar 

  6. Mu Q, Ma Q, Wang Y, Chen Z, Tong X, Chen FF et al. Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol 2012; 91: 1065–1072.

    Article  PubMed  Google Scholar 

  7. Burke BA, Carroll M . BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 2010; 24: 1105–1112.

    Article  CAS  PubMed  Google Scholar 

  8. Hehlmann R . How I treat CML blast crisis. Blood 2012; 120: 737–747.

    Article  CAS  PubMed  Google Scholar 

  9. Fioretos T, Johansson B . Chronic myeloid anchor leukemia. In: Heim S, Mitelman F (eds). Cancer Cytogenetics. Wiley-Blackwell: Hoboken, NJ, USA, 2009; pp 179–207.

    Google Scholar 

  10. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872–884.

    Article  CAS  PubMed  Google Scholar 

  11. Vardiman JW, Melo JV, Baccarani M, Thiele J . Chronic myelogenous leukaemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classifiction of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008; pp 32–37.

    Google Scholar 

  12. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010; 116: 2673–2681.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S et al. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 2010; 95: 1604–1607.

    Article  CAS  PubMed  Google Scholar 

  14. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    Article  CAS  PubMed  Google Scholar 

  15. Wolman SR, Gundacker H, Appelbaum FR, Slovak ML . Southwest Oncology G. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood 2002; 100: 29–35.

    Article  CAS  PubMed  Google Scholar 

  16. Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia 2014; 28: 1754–1758.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    W Wang, P lin, J D Khoury, D Ai, Z Tang, G Tang, J L Jorgensen, L J Medeiros & S Hu

  2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J E Cortes

Authors
  1. W Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J E Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J D Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L Jorgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L J Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Hu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, W., Cortes, J., lin, P. et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia 29, 2263–2266 (2015). https://doi.org/10.1038/leu.2015.96

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.96

This article is cited by

Search

Advanced search

Quick links